Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
Binayak Sinha,1 Kalyan Kumar Gangopadhyay,2 Samit Ghosal31Department of Endocrinology, AMRI Hospital, 2Department of Endocrinology, Fortis and Peerless Hospital, 3Nightingale Hospital, Kolkata, IndiaAbstract: Insulin therapy is not without side effects. In patients with complications on complex reg...
Enregistré dans:
| Auteurs principaux: | Sinha B, Gangopadhyay KK, Ghosal S |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2014
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/c3cd9b184ab64c96921aa90b80cc1f3b |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
par: Wang F, et autres
Publié: (2012) -
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
par: Thuillier P, et autres
Publié: (2015) -
Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
par: Abe S, et autres
Publié: (2011) -
Glargine and degludec: Solution behaviour of higher dose synthetic insulins
par: Gary G. Adams, et autres
Publié: (2017) -
Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
par: Tarigan TJE, et autres
Publié: (2021)